Patents Assigned to Schering Corp.
-
Patent number: 8232372Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.Type: GrantFiled: December 13, 2007Date of Patent: July 31, 2012Assignee: Schering Corp.Inventors: Leonard G. Presta, Rene de Waal Malefyt
-
Publication number: 20120177658Abstract: Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.Type: ApplicationFiled: November 2, 2011Publication date: July 12, 2012Applicant: Schering Corp.Inventors: Pedro A. Reche-Gallardo, Vassilli Soumelis, Yong-Jun Liu, Rene de Waal Malefyt, J. Fernando Bazan, Robert A. Kastelein
-
Patent number: 8088611Abstract: The present invention provides, in part, AKT3 polypeptides and methods of use thereof along with nucleic acids encoding the polypeptides. For example, methods for screening for AKT3 inhibitors are provided herein.Type: GrantFiled: May 21, 2010Date of Patent: January 3, 2012Assignee: Schering Corp.Inventors: Andrew J. Prongay, Thierry O. Fischmann, Chandra C. Kumar, Vincent S. Madison, Joseph E. Myers, Paul Reichert, Rosalinda Syto, William T. Windsor, Li Xiao, Todd W. Mayhood
-
Patent number: 8076335Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.Type: GrantFiled: July 21, 2010Date of Patent: December 13, 2011Assignee: Schering Corp.Inventors: Sydney Ugwu, Vinay Radhakrishnan, Peter M. Ihnat, Lenore C. Witchey-Lakshmanan
-
Patent number: 8075886Abstract: Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.Type: GrantFiled: June 29, 2009Date of Patent: December 13, 2011Assignee: Schering CorpInventors: Pedro A. Reche-Gallardo, Vassili Soumelis, Yong-Jun Liu, Rene de Waal Malefyt, J. Fernando Bazan, Robert A. Kastelein
-
Patent number: 8063185Abstract: The present application relates to methods for growing crystals of both the uncomplexed and complexed forms of ?-secretase (BACE) polypeptide. The present application also relates to crystalline forms of uncomplexed BACE and the three-dimensional structure of BACE, as determined from the crystals. In addition, the present application relates to the use of crystalline forms of BACE to identify ligands, preferably inhibitors (antagonists), which bind to, and preferably inhibit the enzymatic activity of, BACE. Furthermore, the present application relates to nucleic acid sequences encoding BACE polypeptide, and methods for making BACE in greater quantity than prior methods, resulting in more effective crystallization.Type: GrantFiled: May 4, 2009Date of Patent: November 22, 2011Assignee: Schering Corp.Inventors: Brian M. Beyer, Bruce A. Malcolm, Corey O. Strickland, Wenyan Wang, Eileen Wilson
-
Patent number: 8048663Abstract: The present invention relates to Pregnane X receptor (PXR) polypeptides and crystals that are useful, for example, for crystallization and in assays for identification of modulators of PXR.Type: GrantFiled: June 15, 2010Date of Patent: November 1, 2011Assignee: Schering Corp.Inventors: Wenyan Wang, Shahriar Shane Taremi, Winifred Prosise, Paul Reichert, Charles A. Lesburg, Vincent S. Madison, Kuo-Chi Cheng
-
Patent number: 8034907Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.Type: GrantFiled: November 18, 2009Date of Patent: October 11, 2011Assignee: Schering Corp.Inventors: Shahriar Shane Taremi, Gaolian Xie, Thomas Hesson, Jose S. Duca, Corey Strickland, William T. Windsor, Vincent S. Madison, Rumin Zhang, Paul Reichert, Yaolin Wang
-
Patent number: 7824491Abstract: The present invention discloses nucleic acids that encode an active human Aurora 2 kinase catalytic domain. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active human Aurora 2 kinase catalytic domain. The present invention further discloses a crystalline form of a catalytic domain of human Aurora 2 kinase. In addition, the present invention discloses methods of using the X-ray diffractable crystals of human Aurora 2 kinase in structure assisted drug design to identify compounds that can modulate the enzymatic activity of human Aurora 2 kinase.Type: GrantFiled: August 1, 2008Date of Patent: November 2, 2010Assignee: Schering Corp.Inventors: Thierry O. Fischmann, Vincent S. Madison, Alan William Hruza, Paul Reichert, Lata Ramanathan, David Paul Sanden, Wolfgang Seghezzi
-
Patent number: 7824897Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.Type: GrantFiled: February 9, 2010Date of Patent: November 2, 2010Assignee: Schering Corp.Inventors: Brian M. Beyer, Richard N. Ingram, Peter Orth, Corey O. Strickland
-
Patent number: 7786149Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.Type: GrantFiled: September 26, 2007Date of Patent: August 31, 2010Assignees: Schering Corp., Pharmacopeia Drug Discovery, Inc.Inventors: Purakkattle J. Biju, Arthur G. Taveras, J. Robert Merritt, John J. Baldwin, Younong Yu, Junying Zheng, Jianhua Chao, Cynthia J. Aki
-
Patent number: 7192944Abstract: The present invention provides compounds represented by the structural formula (I): or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein each of the substituents is as specified herein, formulations including the above compounds, processes for preparing the same and methods for treating vascular conditions, such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols.Type: GrantFiled: March 3, 2004Date of Patent: March 20, 2007Assignee: Schering Corp.Inventors: Duane A. Burnett, John W. Clader
-
Patent number: 6492381Abstract: A method of inhibiting Ras function and therefore inhibiting cellular growth is disclosed. The method comprises the administration of a compound of Formula 1.0 Also disclosed are novel compounds of the formulas: and Also disclosed are processes for making 3-substituted compounds of the Formulas 1.1, 1.2 and 1.3. Further disclosed are novel compounds which are intermediates in the processes for making the 3-substituted compounds of Formulas 1.1, 1.2, and 1.3.Type: GrantFiled: May 16, 2000Date of Patent: December 10, 2002Assignee: Schering Corp.Inventors: W. Robert Bishop, Ronald J. Doll, Alan K. Mallams, F. George Njoroge, Joanne M. Petrin, John J. Piwinski, Ronald L. Wolin, Arthur G. Taveras, Stacy W. Remiszewski
-
Patent number: 5283359Abstract: The preparation of arylethanolamines, and in particular albuterol (salbutamol), together with their novel boron, acetal and hemi-acetal intermediates is described.Type: GrantFiled: March 1, 1993Date of Patent: February 1, 1994Assignee: Schering Corp.Inventors: Chou-Hong Tann, T. K. Thiruvengadam, John Chiu, Michael Green, Timothy L. McAllister, Cesar Colon, Junning Lee
-
Patent number: 4507294Abstract: There are disclosed herein certain substituted imidazo[1,2-a]pyrazine compounds which are useful in the treatment of peptic ulcer diseases.Type: GrantFiled: March 8, 1982Date of Patent: March 26, 1985Assignee: Schering Corp.Inventors: James A. Bristol, Raymond G. Lovey
-
Patent number: 4477378Abstract: Disclosed are esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1-H-3-benzazepines represented by the general formula I ##STR1## wherein X is chloro, bromo or trifluoromethyl; R.sub.1 is alkyl, aralkyl, aryl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, cycloalkylalkyl, alkoxycarbonylalkyl, cycloalkyl, 1-adamantyl, cycloalkoxyalkyl, alkoxy, aralkoxy, cycloalkoxy or aryloxy; and the pharmaceutically acceptable acid addition salts thereof. The compounds show neuroleptic, antidepressive and antiaggressive activity.Type: GrantFiled: September 9, 1982Date of Patent: October 16, 1984Assignee: Schering Corp.Inventors: Elijah H. Gold, Wei K. Chang
-
Patent number: 4291688Abstract: An inhalation device of the type adapted to receive and locate an aerosol container designed to administer a multiplicity of metered doses, said aerosol container having a composition under pressure therein and having metering valve means including a valve stem and associated metering means, the valve stem having an axial discharge tube extending therethrough for discharge of a metered dose upon actuation of said metering valve means by depression of said valve stem, said inhalation device comprising a body having a skirt adapted to receive and locate said aerosol container in a first end thereof and a head-piece connected to a second end of said skirt, a mouth-piece extending from said head-piece and in communication therewith, and an audible signal generating means, said head-piece having actuating means for said metering valve means and a discharge passageway leading to a discharge orifice directed towards said mouth-piece, said actuating means being engageable with the valve stem upon location of the contType: GrantFiled: December 17, 1979Date of Patent: September 29, 1981Assignee: Schering Corp.Inventor: Frederic E. Kistler